

3^o ENCONTRO NACIONAL DE INVESTIGAÇÃO CLÍNICA & INOVAÇÃO BIOMÉDICA

21 MAIO | ISCTE LISBOA

AICIB | AGÊNCIA DE INVESTIGAÇÃO CLÍNICA E INOVAÇÃO BIOMÉDICA





EP PerMed

European Partnership
for **Personalised Medicine**

eppermed@dlr.de

- **Overview**
- **Outlook**
- **Funding Opportunities**

Carlos Almeida Pereira

AICIB / EP PerMed Task Leader


carlos.pereira@aicib.pt



European Partnerships – objectives:

- accelerate transition to **circular society** and **economy**, with **neutral impact on climate**;
- support the achievement of EU priorities – **European Green Deal, digital age, people-centered economy**, stronger Europe in global terms;
- implement R&I activities, from **concept** phase to **demonstration/validation, adoption** by the market, regulation systems and society;
- contribute to a **stronger European Research Area** (EEA), avoiding duplication of efforts, creating critical scales of investment, reinforcing synergies between programmes.

EP PerMed in the European context



ERA PerMed (2017- 2023)

- 111 interdisciplinary transnational consortia on PM
- Budget: **+130 M€**

CSAs ICPerMed funded (EU)

- 2 Secretariats (2016 – 2024)
- Several European Regions involved
- Leveraging Clinical Trials in PM
- Personalized Prevention Actions
- Economic Assessment of Health in PM
- International Collaboration Efforts on PM in EU

Strategic Research and Innovation Agenda

SRIA



Essential document for **European Partnerships**

- General context EP PerMed
- Identification / elaboration priority areas in R&I, incl. activities for promotion, development and implementation of integrated actions
- Support broad range partners / experts on developing programmes, activities and additional research (prevention and personalized clinical care)
- “Living document”: SRIA updates predicted




abril.2023

Have a look!



www.eppermed.eu/action-areas/sria/

The PM "System of Health"



Structure and Budget of EP PerMed




Ministries (national),
Regional Commissions,
Funding Agencies, & other
(EIT Health, BBMRI...), from
24 countries and 10
regions.

~**100 M€** budget **EC**
~**275 M€** budget **Partners**
**+ 85% total resources for support
3rd Parties**
Additional measures in all WPs
to support PM research,
innovation & implementation

7 years implementation
3 years Phase-Out (finalization
of JTC funded consortia &
Partnership monitoring
activities + measures to ensure
future sustainability of PM
approaches)

Structure & Organization of EP PerMed




General Objectives of EP PerMed

- ▶ Joint alignment, development and implementation of PM **funding** activities and **research** efforts in general (WP2)
- ▶ Support and acceleration of PM **innovations** (WP3)
- ▶ Support and acceleration of PM **implementation** into national and regional health care systems (WP4)
- ▶ **International** and **regional** networking options for all relevant players to ensure PM development and implementation, such as **infrastructures** or medical **societies** (WP5)
- ▶ Diverse PM-related **mapping** efforts, identification and dissemination of **PM achievements** and successes as well as **engagement** and **education** activities (all WPs)
- ▶ Coordination and Management (WP1)



EP PerMed: Calls & Activities

- ▶ First Joint Transnational Call (**JTC2024**)
- ▶ Annual **Joint Transnational Calls** planned until 2030
- ▶ **Additional integrated activities:** support **PM innovation** and implementation of **PM approaches** in Health Systems:
 - **RITC** – *Research, Innovation & Technology Calls*
 - **Network Calls** (Regions)
 - **Survey Calls**
 - **Pilots, Site Visits and Awards**
 - **RTT** – *Reverse Technology Transfer*
 - ...



EP PerMed JTC2024 (**Aims**)

Identification or Validation of Targets for Personalized Medicine Approaches

- ❖ **Identifying or validating targets for PM** in human health in combination with development of companion biomarkers to allow for monitoring of treatment outcomes and patient stratification;
- ❖ Encourage and enable **transnational interdisciplinary collaborations** by combining pre-clinical and clinical research in translational projects, and multi-actor research including end-user perspective;
- ❖ Encourage **cross-sectorial collaborations**, by including the private sector.



The call is open

EP PerMed JTC 2024

“Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets)”



Call Documents

The call text and all additional documents can be downloaded below:

[Call text \(PDF\)](#)

[Guidelines for applicants \(PDF\)](#)



[Pre-proposal form \(DOCX\)](#)

EP PerMed JTC2024 (**SCOPE**)

- ❑ **Stage 1: Identification of novel targets** for the development of a concrete and feasible **PM approach**, based on a clearly circumscribed biological/clinical hypothesis, in combination with companion biomarker research. Applicants are advised to use existing clinical data as a basis for target identification.

- ❑ **Stage 2: Development or validation of** already known but not yet established **targets for a PM approach**, in combination with accompanying biomarker research. This includes target validation in vitro and in animal models (proof-of-principle studies), early pharmacological and toxicity tests and, if feasible, exploratory clinical studies to demonstrate clinical applicability (*proof-of-concept studies*).

- **Exclusion:** *Projects submitted focussing on the identification of new biomarkers as the sole purpose of the research are out of the scope.*



Oportunidades de financiamento: JTC 2024



EP PerMed

European Partnership
for **Personalised Medicine**

www.eppermed.eu/jtc2024/

#PMTargets



Call Summary

“Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets)”

~45 M€

Estimated Call Budget

23 countries

38 funding organizations / 10 national European regions

15 Jan 2024

Info Day

05 Mar 2024

Deadline **pre**-proposals

20 Jun 2024

Deadline **full**-proposals

≈ 2025

Start research projects



EP PerMed

European Partnership
for **Personalised Medicine**

Thank you!

Website: www.eppermed.eu

Email: eppermed@dlr.de

LinkedIn: **EP PerMed - the European Partnership for Personalised
Medicine**

X: **@EPPerMed**